
Alex Melamed
@headofmelon
Followers
1K
Following
2K
Media
107
Statuses
948
Gynecologic Oncology practice @MassGenNews. Researching how real-world cancer care affects real-world patients. He/his/him/himself
Joined March 2013
RT @nagustiga: Our JAMA Oncology study is now featured in the @IJGConline podcast! Thank you for highlighting our work. Grateful to work w….
0
7
0
RT @nagustiga: Our 15-year cohort study explores trends in surgical de-escalation in gynecologic oncology. These findings are transforming….
0
7
0
LANCE trial lead-in pilot shows the feasibility of a phase III study to evaluate the efficacy of MIS for interval cytoreduction in ovarian cancer. @RauhHainMD @annafagottimd @RParejaGineOnco @pedroramirezMD @abedsinno
LANCE RCT: A minimally invasive surgery for advanced ovarian cancer after neoadjuvant chemotherapy is feasible and may reduce postoperative complications compared to laparotomy.
3
12
51
RT @NiteckiRoni: #cancer during #pregnancy is associated with severe maternal and neonatal morbidity. Proud of the entire team for this imp….
0
8
0
Cool picture of a adenosarcoma assocaited uterine inversion which we treated laparoscopically. Nice work by Baran Vardar and @AlexBercowMD getting these pictures into the literature.
0
1
5
NACT and interval cytoreductive surgery edges out primary cytoreductive surgery as the most frequent treatment for advanced-stage ovarian cancer in the US. 11 years after Vergote et al. It really does take a decade.
Since 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery has become the most prevalent approach of upfront treatment for patients with advanced epithelial ovarian cancer in the US.
0
1
13
RT @JAMANetworkOpen: Since 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery has become the most prevalent approach….
0
1
0
Thanks @IJGConline and @pedroramirezMD for this great honor.
📣 Great news!!!.Dr. Alexander Melamed joins the #IJGC #AssociateEditors team 🔥 🔥. Welcome Alex!🤩. @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4
0
2
35
A new paper by super intern Katy Abel looks at the use and efficacy of primary site surgery in metastatic cancer. There is a lot of heterogeneity across cancer sites, raising essential questions about how, and if, we know when surgery is helpful.
onlinelibrary.wiley.com
Purpose To assess the impact of primary-site surgery plus systemic therapy compared to systemic therapy alone on overall survival in common metastatic cancer types. Methods Data sources included E...
0
0
6
A new paper by Jason Silberman @JSilby3: who is on the market for the gyn onc fellowship spot!. cytotoxic NACT has increased for stage III&IV low-grade serous ovarian cancer in last 15y w/o evidence that this approach is effective in this cancer type.
1
3
11
Nice study from Vrede et al:. The molecular subtype may not be prognostically important for low-grade endometrioid endometrial cancer. Relevance of Molecular Profiling in Patients With Low-Grade Endometrial Cancer via @JAMANetworkOpen part of @JAMANetwork
0
5
14
RT @AbbasHassanMD: Our latest study in @JAMASurgery revealed that spending for cancer surgery decreased significantly among Medicare benefi….
0
3
0
RT @emollick: If you last checked in on AI image makers a month ago & thought “that is a fun toy, but is far from useful…” Well, in just th….
0
2K
0